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NOTALGIA PARESTHETICA
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SUMMARY – Notalgia paresthetica is a common, although under-recognized condition charac-
terized by localized chronic pruritus in the upper back, most often aff ecting middle-aged women. 
Apart from pruritus, patients may present with a burning or cold sensation, tingling, surface numb-
ness, tenderness and foreign body sensation. Additionally, patients often present with hyperpigmented 
skin at the site of symptoms. Th e etiology of this condition is still poorly understood, although a 
number of hypotheses have been described. It is widely accepted that notalgia paresthetica is a sen-
sory neuropathy caused by alteration and damage to posterior rami of thoracic spinal nerves T2 
through T6. To date, no well-defi ned treatment has been found, although many treatment modalities 
have been reported with varying success, usually providing only temporary relief.
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Introduction
Notalgia paresthetica (NP) is a common, yet sel-
dom reported condition characterized by chronic pru-
ritus in the interscapular and paravertebral region with 
periodic remissions and exacerbations. Th e disease was 
fi rst described by the Russian neurologist Astwaza-
turow in 1934. Analogous to meralgia paresthetica or 
cheiralgia paresthetica, the name of the disorder is de-
rived from the ancient Greek words noton, “back” and 
algia, “pain”1-3.
Th e disease primarily aff ects adults, more frequent-
ly women than men4, however, some hereditary cases 
have been reported in younger patients (even 6-year-
old children) when it is associated with multiple endo-
crine neoplasia type 2A (MEN 2A)5.
Etiology
Th e exact etiology of NP still has not been fully 
elucidated, however, it is widely accepted that NP is a 
sensory neuropathy caused by alteration and damage 
to the cutaneous branches of the dorsal primary rami 
of thoracic spinal nerves, most commonly T2 through 
T6. Th e posterior rami of spinal nerves T2 through T6 
are anatomically unique in that they pass through the 
multifi dus spinae muscle at a right-angle (90-degree) 
course en route to the epidermis, and therefore may be 
more susceptible to injury, which is why Massey and 
Pleet, as well as Pećina et al. suggested nerve entrap-
ment as the underlying cause of NP (Fig. 1)2,3. Th e 
damage to spinal nerves may be caused by impinge-
ment from degenerative changes in the spine (for ex-
ample, osteoarthritic changes, kyphosis, vertebral hy-
perostosis) or compression by muscle fi bers6-8. Unfor-
tunately, typically there is no strong correlation be-
tween spinal pathology demonstrated on imaging 
studies and the dermatomal localization of symptoms 
in patients with NP9.
Furthermore, increased dermal innervation, various 
viscerocutaneous refl ex mechanisms, neurotoxicity of 
certain chemicals and hereditary susceptibility to pe-
ripheral neuropathy have also been implicated in the 
pathophysiology of NP2,6,10-13. In patients with MEN 
2A, the etiology appears to diff er and an association 
with the codon 634 RET mutation has been reported 
in the literature5,7.
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Clinical Presentation
Patients with NP typically present with intermit-
tent, paroxysmal pruritus, which tends to vary in in-
tensity, and is often accompanied by pain, hyperesthe-
sia and various paresthesias including burning, as well 
as cold sensation, tingling, surface numbness, tender-
ness and foreign body sensation. Th ese sensations are 
usually felt medially or inferior to the scapula and lat-
eral to the thoracic spine. Th e disorder is typically uni-
lateral, however, interscapular and bilateral distribu-
tion of symptoms has also been reported6,14. Th ere are 
usually no known triggering or alleviating factors, al-
though one review in the literature suggests that pa-
tients with MEN 2A demonstrate amelioration of 
symptoms following exposure to sunlight7.
A typical dermatologic fi nding is hyperpigmenta-
tion of the aff ected area with irregular and indistinct 
borders with occasional keratotic or atrophic surfaces; 
it has been reported in two-thirds of published cases in 
the literature (Fig. 2)6. Th is skin manifestation is be-
lieved to be a result of chronic scratching and rubbing 
or, as other authors have suggested, a consequence of 
neurogenic release of substance P into the skin, which 
not only leads to pruritus, but also causes proliferation 
of epidermal cells, arterial smooth muscle cells and fi -
broblasts15,16.
Diagnosis
Th e diagnosis of NP is most frequently made on 
the basis of reported symptoms and specifi c area af-
fected. Physical examination and detailed medical his-
tory regarding vertebral and thoracic trauma, degen-
erative disorders or malignancies, vertebral fracture, 
cervical disc disease, osteoarthritis and familial history 
should be obtained, while in certain cases imaging 
methods may be considered4,6,7,17. Since NP can be an 
early manifestation of MEN 2A, in younger patients a 
blood test to check the level of calcitonin should be 
performed as a screening method for medullary thy-
roid carcinoma6,7,18.
In addition, other more common pruritic diseases 
such as pigmented contact dermatitis, pityrosporum 
folliculitis, parapsoriasis, neurodermatitis and primi-
tive cutaneous amyloidosis should be excluded prior to 
Fig. 2. Bilateral hyperpigmentation in a 59-year-old 
patient with notalgia paresthetica.
Fig. 1. Modifi ed schematic illustration: entrapment 
of the dorsal nerve branches of thoracic roots at their 
passage through the multifi dus spine muscle: 1: ganglion 
trunci sympathici; 2: spinal ganglion; 3: dorsal branch 
of the thoracic root; 4: medial branch; 5: lateral branch; 
6: ventral branch of the thoracic root (adapted from: 
Pećina MM, Krmpotić-Nemanić J, Markiewitz AD. 
Tunnel Syndromes: Peripheral Nerve Compression 
Syndromes. 3rd edn. Boca Raton, London, New York, 
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Table 1. Treatment alternatives for notalgia paresthetica
Topical
Capsaicin19,20 0.025% cream 5 x daily for 1 week, followed by 3 x daily for 5 weeks: 70% of patients reported 
improvement, however, most experienced relapse within a month after treatment;
8% patches: 3 patients experienced immediate relief of itch, duration varied considerably
Tacrolimus21 0.1% ointment twice daily: reduction in both intensity and frequency of itch was reported 
in 5 of 7 patients after 6 weeks of treatment, a tolerable burning sensation was the only side 
eff ect reported, symptoms generally returned after discontinuation of treatment
Anesthetics22 Lidocaine and prilocaine cream under occlusion 2 x daily: complete resolution of symptoms 




4 U per superfi cial injection, spaced 2 cm apart:
16 U in one patient, 72 U in another patient led to resolution of pruritus and decrease 
of hyperpigmentation for over 18 months;
another study in 5 patients and later a randomized, placebo-controlled, double-blind clinical trial 
in 20 patients failed to replicate these results
Corticosteroids26 Triamcinolone 2.5 mg/mL: success in treatment of 2 patients
Oral
Oxcarbazepine27 6-month treatment, initial dose of 300 mg twice daily and increased to 600 mg twice daily 
or 900 mg twice daily to achieve adequate relief: alleviation of symptoms in 4 out of 5 patients, 
1 patient withdrew due to side eff ects (dizziness and headache)
Gabapentin28,29 Initiated at a dose of 300 mg at night and increased to 600 mg at night: resulted in absolute 
resolution of pruritus in 1 patient, after discontinuation of treatment, pruritus returned;
300 mg/day for 4 weeks: improvement in itching observed in all patients, side eff ects 
(mild gastric discomfort, dizziness) were well tolerated
Amitriptyline30 10 mg daily for 9 months: satisfactory reduction of pruritus in 1 patient, sustained for at least 
1 month after stopping treatment
Other
Surgery31 Surgical decompression of the cutaneous nerve: resolution of pruritus for at least 4 months in 1 patient
Nerve block32 Local anesthetic block in 1 patient using 5 mL of 0.75% bupivacaine combined with 40 mg 
of methylprednisolone acetate achieved disappearance of symptoms for over 1 year
TENS33 5 sessions a week for 2 weeks, 50-100 Hz, 20 min duration, 40-75 μs pulse width: mostly mild 
amelioration of itch was attained in a group of 15 patients
EMS15 30 seconds on and 30 seconds off  for 15 minutes twice daily, 70 Hz with a pulse width of 300 μs: 
relief of pain beginning within days upon starting EMS, recurrence of pain after discontinuation 
of stimulation for a prolonged period of time, maintenance of analgesic eff ects with only 
intermittent stimulation in 4 cases of NP with injury to the long thoracic nerve
Narrow band 
UV-B13
Mean of 32.8 sessions and mean cumulative dose of 33.76 J⁄cm2: relevant improvement, 




20-min session, suboccipital decompression, muscle energy, inhibition and other soft tissue 
techniques, fascia release: improvement of symptoms in 1 patient
Acupuncture35 Deep intramuscular stimulation acupuncture to the paravertebral muscles in the aff ected area, 
2-6 treatments: in 16 patients, absolute or partial alleviation of pruritus was observed, relapse 
occurred within 1-12 months 
Exercise36 Stretching and strengthening exercises that elongate the spine and strengthen postural muscles: 
resolution of symptoms in 2 patients
Physiotherapy6 Spinal and paraspinal physiotherapy (ultrasound, radiation, multimodal physiotherapy): 
4 of 6 patients showed improvement of symptoms that lasted for 1-9 years
TENS = transcutaneous electrical nerve stimulation; EMS = electrical muscle stimulation
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diagnosing a patient with NP, which is commonly a 
clinical diagnosis of exclusion6.
Treatment
Management of NP is diffi  cult and still presents a 
clinical challenge, as the condition is often resistant to 
multiple therapies. Just as the pathogenesis of NP re-
mains unclear, there is no well-defi ned treatment, al-
though numerous treatment modalities have been re-
ported, with variable results. Conventional antipruritic 
therapies such as antihistamines and topical cortico-
steroids do not address the neuropathic origin of NP 
and show poor eff ect6.
Potential treatment includes topical anesthetics, 
capsaicin and tacrolimus, intralesional corticosteroids, 
cutaneous botulinum toxin type A injections, gaba-
pentin, oxcarbazepine, amitriptyline, surgical decom-
pression, paravertebral local anesthetic blocks, transcu-
taneous electrical nerve stimulation (TENS), electrical 
muscle stimulation (EMS), exposure to narrow band 
UV-B radiation, spinal manipulation, physical therapy 
applications, osteopathic manipulative treatment and 
acupuncture (Table 1). Most of these therapeutic op-
tions have been described in a small number of pa-
tients and with varying degrees of success.
Conclusion
Th ere are fewer than 100 cases of NP described in 
the scientifi c literature to date. Although it is not a 
severe disorder per se, the lack of effi  cient treatment 
and understanding of the condition greatly aff ects pa-
tient quality of life. Th erefore, further research regard-
ing the underlying pathophysiology is of great impor-
tance in order to appropriately manage and treat NP 
patients.
References
 1. Ellis C. Notalgia paresthetica: the unreachable itch. Derma-
tol Pract Concept. 2013;3(1):3-6, http://dx.doi.org/10.5826/
dpc.0301a02
 2. Massey EW, Pleet AB. Notalgia paresthetica. JAMA. 1979;
241(14):1464.
 3. Pećina MM, Krmpotić-Nemanić J, Markiewitz AD. Tunnel 
Syndromes: Peripheral Nerve Compression Syndromes. 3rd 
edn. Boca Raton, London, New York, Washington D.C.: CRC 
Press; 2001. p. 167-70.
 4. Chiriac A, Podoleanu C, Moldovan C, Stolnicu S. Notalgia 
paresthetica, a clinical series and review. Pain Pract. 2016;
16(5):E90-1, http://dx.doi.org/10.1111/papr.12436
 5. Alcántara F, Feito M, Albizuri F, Beato M, De Lucas R. Notal-
gia paresthetica and multiple endocrine neoplasia syndrome 2a: 
a case report. Pediatr Dermatol. 2016;33(5):e303-5, http://
dx.doi.org/10.1111/pde.12907
 6. Raison-Peyron N, Meunier L, Acevedo M, Meynadier J. No-
talgia paresthetica: clinical, physiopathological and therapeutic 
aspects. A study of 12 cases. J Eur Acad Dermatol Venereol. 
1999;12(3):215-21.
 7. Shumway NK, Cole E, Fernandez KH. Neurocutaneous dis-
ease: neurocutaneous dysesthesias. J Am Acad Dermatol. 
2016;74(2):215-28, 
 http://dx.doi.org/10.1016/j.jaad.2015.04.059
 8. Savk E, Savk O, Bolukbasi O, Culhaci N, Dikicioğlu E, Kara-
man G, Sendur N. Notalgia paresthetica: a study on pathogen-
esis. Int J Dermatol. 2000;39(10):754-9.
 9. Huesmann T, Cunha PR, Osada N, Huesmann M, Zanelato 
TP, Phan NQ, Gontijo GM, Marziniak M, Ständer S. Notalgia 
paraesthetica: a descriptive two-cohort study of 65 patients 
from Brazil and Germany. Acta Derm Venereol. 2012;92
(5):535-40, http://dx.doi.org/10.2340/00015555-1344
10. Springall DR, Karanth SS, Kirkham N, Darley CR, Polak JM. 
Symptoms of notalgia paresthetica may be explained by in-
creased dermal innervation. J Invest Dermatol. 1991;97(3):
555-61.
11. Eisenberg E, Barmeir E, Bergman R. Notalgia paresthetica as-
sociated with nerve root impingement. J Am Acad Dermatol. 
1997;37(6):998-1000.
12. Savk O, Savk E. Investigation of spinal pathology in notalgia 
paresthetica. J Am Acad Dermatol. 2005;52(6):1085-7, http://
dx.doi.org/10.1016/j.jaad.2005.01.138
13. Pérez-Pérez L, Allegue F, Fabeiro JM, Caeiro JL, Zulaica A. 
Notalgia paresthesica successfully treated with narrow-band 
UVB: report of fi ve cases. J Eur Acad Dermatol Venereol. 
2010;24(6):730-2, 
 http://dx.doi.org/10.1111/j.1468-3083.2009.03479.x
14. Shin J, Kim YC. Neuropathic itch of the back: a case of notalgia 
paresthetica. Ann Dermatol. 2014;26(3):392-4, http://dx.doi.
org/10.5021/ad.2014.26.3.392
15. Wang CK, Gowda A, Barad M, Mackey SC, Carroll IR. Ser-
ratus muscle stimulation eff ectively treats notalgia paresthetica 
caused by long thoracic nerve dysfunction: a case series. J Bra-
chial Plex Peripher Nerve Inj. 2009;4:17, http://dx.doi.
org/10.1186/1749-7221-4-17
16. Tanaka T, Danno K, Ikai K, Imamura S. Eff ects of substance P 
and substance K on the growth of cultured keratinocytes. J In-
vest Dermatol. 1988;90(3):399-401.
17. Alai NN, Skinner HB, Nabili ST, Jeff es E, Shahrokni S, Saemi 
AM. Notalgia paresthetica associated with cervical spinal ste-
nosis and cervicothoracic disk disease at C4 through C7. Cutis. 
2010;85(2):77-81.
Mirna Šitum et al. Notalgia paresthetica
Acta Clin Croat, Vol. 57, No. 4, 2018 725
18. Pérez-Pérez LC. General features and treatment of notalgia 
paresthetica. Skinmed. 2011;9(6):353-8.
19. Wallengren J, Klinker M. Successful treatment of notalgia pares-
thetica with topical capsaicin: vehicle-controlled, double-blind, 
crossover study. J Am Acad Dermatol. 1995;32(2 Pt 1):287-9.
20. Andersen HH, Sand C, Elberling J. Considerable variability in 
the effi  cacy of 8% capsaicin topical patches in the treatment of 
chronic pruritus in 3 patients with notalgia paresthetica. Ann 
Dermatol. 2016;28(1):86-9, 
 http://dx.doi.org/10.5021/ad.2016.28.1.86
21. Ochi H, Tan LX, Tey HL. Notalgia paresthetica: treatment 
with topical tacrolimus. J Eur Acad Dermatol Venereol. 2016;
30(3):452-4, http://dx.doi.org/10.1111/jdv.12830
22. Layton AM, Cotterill JA. Notalgia paraesthetica – report of 
three cases and their treatment. Clin Exp Dermatol. 1991;
16(3):197-8.
23. Pérez-Pérez L, García-Gavín J, Allegue F, Caeiro JL, Fabeiro 
JM, Zulaica A. Notalgia paresthetica: treatment using intrader-
mal botulinum toxin A. Actas Dermosifi liogr. 2014;105(1):
74-7, http://dx.doi.org/10.1016/j.adengl.2013.09.003
24. Weinfeld PK. Successful treatment of notalgia paresthetica 
with botulinum toxin type A. Arch Dermatol. 2007;143(8):
980-2, http://dx.doi.org/10.1001/archderm.143.8.980
25. Maari C, Marchessault P, Bissonnette R. Treatment of notalgia 
paresthetica with botulinum toxin A: a double-blind ran-
domized controlled trial. J Am Acad Dermatol. 2014;70
(6):1139-41, http://dx.doi.org/10.1016/j.jaad.2013.12.006
26. Weber PJ, Poulos EG. Notalgia paresthetica. Case reports and his-
tologic appraisal. J Am Acad Dermatol. 1988;18(1 Pt 1):25-30.
27. Savk E, Bolukbasi O, Akyol A, Karaman G. Open pilot study 
on oxcarbazepine for the treatment of notalgia paresthetica. J 
Am Acad Dermatol. 2001;45(4):630-2, 
 http://dx.doi.org/10.1067/mjd.2001.116228
28. Maciel AA, Cunha PR, Laraia IO, Trevisan F. Effi  cacy of 
 gabapentin in the improvement of pruritus and quality of life 
of patients with notalgia paresthetica. An Bras Dermatol. 
2014;89(4):570-5, 
 http://dx.doi.org/10.1590/abd1806-4841.20142777
29. Loosemore MP, Bordeaux JS, Bernhard JD. Gabapentin treat-
ment for notalgia paresthetica, a common isolated peripheral 
sensory neuropathy. J Eur Acad Dermatol Venereol. 
2007;21(10):1440-1, 
 http://dx.doi.org/10.1111/j.1468-3083.2007.02256.x
30. Yeo B, Tey HL. Eff ective treatment of notalgia paresthetica 
with amitriptyline. J Dermatol. 2013;40(6):505-6, 
 http://dx.doi.org/10.1111/1346-8138.12154
31. Williams EH, Rosson GD, Elsamanoudi I, Dellon AL. Sur-
gical decompression for notalgia paresthetica: a case report. 
Microsurgery. 2010;30(1):70-2, 
 http://dx.doi.org/10.1002/micr.20702
32. Goulden V, Toomey PJ, Highet AS. Successful treatment of 
notalgia paresthetica with a paravertebral local anesthetic 
block. J Am Acad Dermatol. 1998;38(1):114-6.
33. Savk E, Savk O, Sendur F. Transcutaneous electrical nerve 
stimulation off ers partial relief in notalgia paresthetica patients 
with a relevant spinal pathology. J Dermatol. 2007;34(5):315-9, 
http://dx.doi.org/10.1111/j.1346-8138.2007.00279.x
34. Richardson BS, Way BV, Speece AJ 3rd. Osteopathic manipula-
tive treatment in the management of notalgia paresthetica. J 
Am Osteopath Assoc. 2009;109(11):605-8.
35. Stellon A. Neurogenic pruritus: an unrecognised problem? A 
retrospective case series of treatment by acupuncture. Acupunct 
Med. 2002;20(4):186-90.
36. Fleischer AB, Meade TJ, Fleischer AB. Notalgia paresthetica: 




M. Šitum, M. Kolić, N. Franceschi i M. Pećina
Notalgia paresthetica je učestalo, iako slabo prepoznato stanje koje obilježava lokalizirani kronični pruritus gornjeg dijela 
leđa, a najčešće se javlja u žena srednje životne dobi. Uz svrbež u bolesnika se također može javiti osjećaj žarenja ili hladnoće, 
trnci, utrnulost, osjetljivost i osjećaj stranog tijela. Uz to, na mjestu simptoma često se javlja područje hiperpigmentirane kože. 
Iako postoji više hipoteza, etiologija ove bolesti slabo je poznata. Opće je prihvaćeno da je notalgia paresthetica senzorna 
 neuropatija uzrokovana oštećenjem stražnjih ogranaka torakalnih kralježničnih živaca od T2 do T6. Unatoč mnogim razli-
čitim terapijskim metodama koje su bile promjenjivoga uspjeha i najčešće pružale privremeno olakšanje, do danas nema 
uspješnoga liječenja ove bolesti.
Ključne riječi: Pruritus; Notalgia, bolesti; Parestezija; Hiperestezija
